Publication: 4559

Publication: 4559

Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

PubMed

DOI

Google Scholar

Citation:: Eur J Cancer vol 227 115694

Year:: 2025
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: Alliance-data-source,-external-user
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: 2292
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: BMS, Genentech, Pfizer, Sanofi
Grants:: U10CA180821, U10CA180882, UG1CA233180, UG1CA232760, UG1CA233253, UG1CA233327, UG1CA233337, UG1CA233373, ; U10CA180888, UG1CA180830 (SWOG)

Corr. Author:
Authors:: Francesca Battaglin Bert H O'Neil Sebastian Stintzing Fang-Shu Ou Tyler J Zemla Donna Niedzwiecki Federico Innocenti Howard S Hochster Ludwig Fischer von Weikersthal Thomas Decker Alexander Kiani Ursula Vehling-Kaiser Tobias Heintges Christian Lerchenmüller Lena Weiss Kathrin Heinrich Richard M Goldberg Robert J Mayer Richard L Schilsky Charles D Blanke Alan P Venook Heinz-Josef Lenz Volker Heinemann

Networks:: CA011, CA824, LAPS-IL057, LAPS-IN007, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-OH007, OR013

Study: Alliance-A152001
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-80405
Phases:: N/A, 3

Keywords: